Hypofractionated Radiotherapy for Hematologic Malignancies during the COVID-19 Pandemic and Beyond
Purpose: Radiotherapy is integral in the management of hematological malignancies (HM). Standard radiotherapy dose fractionation regimens range between 20 and 50 Gy in 10–25 fractions over 2–5 weeks. This study presents the outcomes of patients with HM treated with hypofractionation radiotherapy (HF...
Furkejuvvon:
| Váldodahkkit: | , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
MDPI AG
2024-01-01
|
| Ráidu: | Current Oncology |
| Fáttát: | |
| Liŋkkat: | https://www.mdpi.com/1718-7729/31/1/25 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|